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arthritis. It has since been approved for further indications 
including juvenile idiopathic arthritis, psoriatic arthritis, 
ankylosing spondylitis, CD, UC, hidradenitis suppurativa, 
psoriasis, and panuveitis. However, it has not been approved 
for intestinal BD. In Japan, a phase 3, non-randomized, 
non-controlled, single-arm clinical trial tested adalimumab 
for intestinal BD refractory to conventional therapy. Of 20 
patients, 60% achieved marked improvement at week 52 
and 20% achieved complete remission at weeks 24 and 
52.4 Based on this open-label clinical trial and case reports, 
adalimumab was recently approved and recommended as 
a standard therapy for intestinal BD in Japan, Taiwan, and 
South Korea.5,6 More evidence should be accumulated for 
the concrete conclusion that adalimumab is effective in the 
treatment of intestinal BD.
The study by Inoue et al.7 was a follow-up extension study 
of the aforementioned phase 3 study. The authors found that 
100 weeks of long-term adalimumab treatment for patients 
with intestinal BD who were refractory to conventional ther-
apy was effective without any significant unexpected adverse 
events. Of the 20 patients enrolled in this study, 60% of pa-
tients at week 52 and 40% of patients at week 100 achieved 
marked improvement; 20% of patients at week 52 and 15% 
of patients at week 100 achieved complete remission. The 
improvement of both clinical and endoscopic disease activi-
ties in patients with refractory intestinal BD was observed. 
The incidence of adverse events during the study was 544.4 
events per 100 person-years (190 events) at week 100, which 
was comparable to 560.4 events per 100 person-years (102 
Intestinal Behçet’s disease (BD), which has pathogenesis 
and clinical features similar to IBD, tends to occur more 
prevalently in East Asian countries than Western or Medi-
terranean regions.1 Since intestinal BD is often refractory to 
conventional treatment such as corticosteroids and immu-
nomodulators, alternative therapies are eventually needed. 
Currently, anti-tumor necrosis factor α (anti-TNF-α) agents 
have greatly improved management of IBD.2 Given this evi-
dence, these agents are also under active investigation in the 
treatment of intestinal BD. 
Infliximab is a chimeric monoclonal antibody-based bio-
logic drug that has been reported to be effective for induc-
ing and maintaining remission in patients with intestinal 
BD. A clinical remission of intestinal lesions and the rapid 
healing of ulcers after treatment of infliximab was reported 
in several studies.3 Fewer reports have described the use of 
adalimumab in intestinal BD rather than infliximab. Adali-
mumab is a completely humanized Ig 1 monoclonal anti-
TNF-α antibody that binds to TNF-α and prevents it from 
binding to its receptors. It was the third TNF-α inhibitor, after 
infliximab and etanercept, to be approved by the U.S. Food 
and Drug Administration for the treatment of rheumatoid 
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events) at week 52. The incidence of serious adverse events 
was 5.5 events per 100 person-years (1 event) and that of 
severe adverse events was 0 events per 100 person-years at 
week 52. Moreover, at week 100, the incidence of serious ad-
verse events was 25.8 events per 100 person-years (9 events) 
and that of severe adverse events was 8.6 events per 100 
person-years (3 events). Serious adverse effects after week 
52 were considered to be related to intestinal BD itself wors-
ening in these individuals, because 8 serious adverse events 
with onset after week 52 were observed in 3 patients, and 6 
out of 8 events affected the gastrointestinal system. Addition-
ally, Lee et al.3 reported that the clinical remission rates after 
infliximab use at 2, 4, 30, and 54 weeks were 32.1%, 28.6%, 
46.2%, and 39.1%, respectively in a Korean multicenter study. 
There was 1 serious infection, but no malignancies or deaths 
in this study. More recently, an open-label, single-arm, phase 
3 study conducted on 18 patients suggested that infliximab 
induced the healing of main intestinal ulcers in 80% of pa-
tients at week 14. There was 1 intestinal BD patient who 
suffered serious adverse events, which included worsening 
of the underlying disease and cataracts. These findings are 
consistent with those of the adalimumab study conducted 
by Inoue et al.7
There have been several studies on the long-term effects 
of adalimumab in IBD. In the previous 52-week, randomized 
controlled study of patients with UC called ULTRA2 (Ulcer-
ative Colitis Long-Term Remission and Maintenance with 
Adalimumab 2; treatment of moderate to severe UC), 17.3% 
of patients showed clinical remission receiving adalimumab 
and 8.5% of patients receiving placebo showed remission at 
week 52.8 In the 56-week, randomized controlled study of pa-
tients with moderate to severe CD called CHARM (Crohn’s 
trial of the fully Human Antibody Adalimumab for Remis-
sion Maintenance), clinical remission rates of 36% were seen 
in patients receiving 40 mg of adalimumab every other week, 
41% of patients receiving 40 mg of adalimumab weekly, and 
12% of patients receiving placebo.9 In the EXTEND (Extend 
the Safety and Efficacy of Adalimumab through Endoscopic 
Healing) trial, 36% of patients with CD achieved clinical re-
mission at week 52. Furthermore, the 52-week, multi-center, 
randomized, prospective, open-label trial of patients with 
CD called DIAMOND (Deep Remission of Immunomodula-
tor and Adalimumab Combination Therapy for Crohn’s Dis-
ease) reported that the clinical remission rates at 4, 26, and 
52 weeks were 77.6%, 63.8%, and near 60%, respectively.10 
Therefore, the effect of adalimumab in intestinal BD might 
not be significantly different from that in UC patients. 
Of note, 20% of patients at week 52 and 15% of patients 
at week 100 achieved complete remission with the use of 
adalimumab in refractory intestinal BD.7 According to a 
recent study, the mean percentage of a loss of response to 
adalimumab in patients with CD was 18.2%, and the annual 
risk of loss of response was 20.3% per patient-year. A lack of 
response to adalimumab developed in 28.5% to 36% of pa-
tients with UC and loss of response varied between 9 and 18 
months. Compared with previous study results, the efficacy 
of adalimumab in intestinal BD seems to last longer than IBD 
patients. This possible effect should be further investigated.
Accurate interpretation of this study by Inoue et al.7 is lim-
ited by the small population and the lack of a control group. 
Despite this, it provided useful information regarding the 
long-term outcome of adalimumab in patients with intes-
tinal BD who were refractory to conventional treatments. 
Adalimumab is a promising treatment option for patients 
with refractory intestinal BD. However, long-term, large-
scale, randomized controlled study is yet to be undertaken. 
Other aspects of the use of TNF-α inhibitors that warrant 
further exploration include their optimal indications and 
dosages, as well as whether switching between them should 
be considered when a lack of adequate response to initial 
TNF-α inhibitor treatment is observed.
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